Abstract
An estimated 8090 new cases of testicular cancer were diagnosed in the United States in 2008. Although relatively uncommon overall, germ cell tumors (GCTs) constitute the most common solid tumor in men between the ages of 15 and 34 years. The worldwide incidence of these tumors has more than doubled in the past 40 years. More than 90% of patients diagnosed with GCTs are cured, including 70% to 80% of patients with advanced tumors who are treated with chemotherapy. Standard therapy has been established at essentially all stages of management and must be closely followed to ensure the potential for cure. Updates to the 2009 NCCN Guidelines include the addition of doses for single-agent carboplatin for seminoma and changes to category 1 for recommendations on radiotherapy and surveillance.
Original language | English (US) |
---|---|
Pages (from-to) | 672-693 |
Number of pages | 22 |
Journal | JNCCN Journal of the National Comprehensive Cancer Network |
Volume | 7 |
Issue number | 6 |
DOIs | |
State | Published - Jun 2009 |
Keywords
- Alpha-fetoprotein
- Cisplatin
- Germ cell tumors
- Human chorionic gonadotropin
- Lactate dehydrogenase
- NCCN Clinical Practice Guidelines
- Nonseminoma
- Seminoma
- Testicular cancer
ASJC Scopus subject areas
- Oncology